# Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization

> **NCT02797704** · PHASE1,PHASE2 · TERMINATED · sponsor: **Rabin Medical Center** · enrollment: 6 (actual)

## Conditions studied

- Corneal Neovascularization

## Interventions

- **DRUG:** Aflibercept

## Key facts

- **NCT ID:** NCT02797704
- **Lead sponsor:** Rabin Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-02
- **Primary completion:** 2019-09-04
- **Final completion:** 2019-09-10
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** the treatment was found to be inefficient for all recruited patients
- **Last updated:** 2019-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02797704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02797704, "Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02797704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*